Inhibrx Biosciences (NASDAQ:INBX) Director Jon Faiz Kayyem Acquires 5,000 Shares

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Director Jon Kayyem acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were purchased at an average cost of $113.52 per share, with a total value of $567,600.00. Following the completion of the transaction, the director owned 424,360 shares in the company, valued at approximately $48,173,347.20. The trade was a 1.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Inhibrx Biosciences Stock Down 5.6%

INBX stock traded down $6.83 during trading on Tuesday, hitting $114.34. 1,672,141 shares of the company’s stock were exchanged, compared to its average volume of 319,653. The business has a 50-day moving average price of $97.77 and a two-hundred day moving average price of $92.51. The company has a current ratio of 5.07, a quick ratio of 5.07 and a debt-to-equity ratio of 12.58. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -12.88 and a beta of 3.66. Inhibrx Biosciences, Inc. has a 52-week low of $26.19 and a 52-week high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). As a group, equities research analysts expect that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current year.

Inhibrx Biosciences News Summary

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: INBRX-106 significantly improved treatment outcomes. In the randomized HexAgon study of first-line patients with PD-L1-positive head and neck squamous cell carcinoma, INBRX-106 combined with pembrolizumab produced a 48.3% confirmed overall response rate, compared with 26.5% for pembrolizumab alone. Interim median progression-free survival was 9.6 months, and 72.4% of combination-treated patients remained progression-free at six months versus 42.8% in the control group. Inhibrx Phase 2 HNSCC study results
• Positive Sentiment: Results were particularly strong in HPV-positive patients. The combination achieved an 80.0% response rate versus 33.3% with pembrolizumab alone, a 30.0% complete-response rate versus 0%, and six-month progression-free survival of 90.0% versus 33.0%. The company plans to add approximately 50 HPV-positive patients, potentially supporting an accelerated-approval pathway and broader use in immunogenic tumors. Reuters report on Inhibrx cancer study
• Positive Sentiment: Insider purchases added a confidence signal. CEO Mark Lappe bought 25,000 shares for approximately $2.65 million, while Director Douglas Forsyth purchased 2,500 shares for about $287,000. These open-market purchases may reinforce investor confidence following the clinical update. CEO SEC Form 4 filing
• Neutral Sentiment: Trading was temporarily halted for pending news. The halt reflects the significance and expected market impact of the clinical announcement, but it does not itself indicate the eventual trading direction. Inhibrx shares and Phase 2 data

Analysts Set New Price Targets

INBX has been the subject of several research reports. HC Wainwright started coverage on Inhibrx Biosciences in a research note on Monday, August 24th. They set a “buy” rating and a $245.00 price target for the company. Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a report on Thursday, August 27th. Wall Street Zen downgraded Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $197.50.

Institutional Trading of Inhibrx Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of INBX. Strs Ohio purchased a new stake in shares of Inhibrx Biosciences in the first quarter valued at $27,000. Russell Investments Group Ltd. lifted its position in Inhibrx Biosciences by 11.0% during the second quarter. Russell Investments Group Ltd. now owns 29,993 shares of the company’s stock worth $428,000 after buying an additional 2,963 shares during the period. Invesco Ltd. acquired a new stake in Inhibrx Biosciences in the 2nd quarter worth about $193,000. Bank of America Corp DE boosted its stake in Inhibrx Biosciences by 19.2% in the 2nd quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock worth $130,000 after buying an additional 1,469 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in Inhibrx Biosciences in the 2nd quarter valued at about $235,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.